Oncology:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      *Remission is based on CR, ORR and PR. CR is defined in the SmPC as complete remission.
      UK-VNCCLL-220184 | May 2022

      VENCLYXTO®  (venetoclax) plus obinutuzumab

      1 year fixed treatment duration for first-line adult CLL patients1

      UK-VNCCLL-220185 | May 2022

      UK-VNCCLL-230003. Date of Preparation: March 2023.

      Venclyxto combinations provide chemo-free fixed-duration treatments that offer your CLL patients the opportunity for sustained survival without continuous treatment1,4,5

       

      Efficacy
      Efficacy and Safety
      Dosing
      Dosing and Administration
      resources
      Resources
      Contact
      Contact AbbVie
      resources
      Frontiers
      Contact
      Congresses

      VENCLYXTO (venetoclax) has three licenced indications1

      VENCLYXTO in combination with obinutuzumab (Ven+O) is indicated for the treatment of adult patients with previously untreated CLL

      VENCLYXTO in combination with rituximab (Ven+R) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy

      VENCLYXTO is licensed as monotherapy (Ven mono), for the treatment of adult patients with CLL:

      • in the absence of del(17p) or TP53 mutations and who have failed both chemoimmunotherapy and a BCRI
      • in the presence of del(17p) or TP53 mutations and who are either unsuitable for, or have failed a BCRI

      BRCI=B-cell receptor pathway inhibitor; CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.

      References

      1. VENCLYXTO Summary of Product Characteristics.
      2. Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
      3. Fischer K et al. N Engl J Med. 2019; 380: 2225–36.
      4. Al-Sawaf O et al. EHA2021 Abstract S146. https://library.ehaweb.org/eha/2021 (accessed April 2023).
      5. Kater AP et al. ASH 2020. Oral Abstract 125. Available from: https://ash.confex.com/ash/2020 (accessed April 2023).

       

      VENCLYXTO PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected]

      UK-VNCCLL-230163. Date of preparation: April 2023.